Skip to content
value.today

Skye Bioscience Inc.

SKYE
$7 Mmarket cap on Oct 29, 2026
Compare
World rank
#26,541
Revenue
—
For year ending December-2025
Net income
$-56 M
SEC filing
Employees
12
As of March 9, 2026
SEC filing

Skye Bioscience Inc. in brief

Skye Bioscience Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $7 M on 29 October 2026, which makes it the 26,541st largest listed company in the world and the 4,356th largest in the USA on this site. It employs about 12 people and Punit Dhillon is its chief executive. Its shares trade under the symbol SKYE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Skye Bioscience Inc.

Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1—a key GPCR involved in metabolic regulation.

We believe there is a growing demand for therapies that offer improved safety, efficacy, tolerability, quality of life and long-term health outcomes while addressing the limitations of currently approved treatments. Our objective is to drive innovation in the treatment landscape for obesity, overweight and metabolic disorders by developing potential first-in-class therapies that meet significant unmet medical needs globally.

From the company's annual report filed with the US SEC: read the report

Skye Bioscience Inc. timeline

5 events, 2011–2021
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2012
  4. ✎
    Renamed Load Guard Logistics, Inc.
    Formerly Load Guard Transportation, Inc..
  5. 2014
  6. ✎
    Renamed Nemus Bioscience, Inc.
    Formerly Load Guard Logistics, Inc..
  7. 2019
  8. ✎
    Renamed Emerald Bioscience, Inc.
    Formerly Nemus Bioscience, Inc..
  9. 2021
  10. ✎
    Renamed Skye Bioscience, Inc.
    Formerly Emerald Bioscience, Inc..

Events of Skye Bioscience Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$7 M$14 M$21 M$28 M2023202420252026

World rank over time

▲ up 2,205 places since 2022
2022-01-07: #28756#28,75620222026-03-08: #11941#11,94120262026-08-01: #22013#22,01320262026-10-08: #26402#26,40220262026-10-29: #26551#26,5512026

Rank in USA: #5,258 (Jan 2022) · #2,296 (Mar 2026) · #3,963 (Aug 2026) · #4,299 (Oct 2026) · #4,359 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.3×
Free cash flow yield
-640.9%
Net margin
—
Operating margin
—
Return on equity
-279.3%
Liabilities / assets
29.3%
Profit per employee
$-4.7 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-19M—FY18Fiscal year ending Dec 2019: revenue —, net income $1M—FY19Fiscal year ending Dec 2020: revenue —, net income $-7M—FY20Fiscal year ending Dec 2021: revenue —, net income $-9M—FY21Fiscal year ending Dec 2022: revenue —, net income $-19M—FY22Fiscal year ending Dec 2023: revenue —, net income $-38M—FY23Fiscal year ending Dec 2024: revenue —, net income $-27M—FY24Fiscal year ending Dec 2025: revenue —, net income $-56M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-58M$-56M—
Dec 2024——$-30M$-27M—
Dec 2023——$-35M$-38M—
Dec 2022——$-18M$-19M—
Dec 2021——$-8M$-9M—
Dec 2020——$-6M$-7M—
Dec 2019——$-7M$1M—
Dec 2018——$-5M$-19M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-43M$0M$-43M$-1.41—
Dec 2024$-25M$2M$-27M$-0.73—
Dec 2023$-14M$0M$-14M$-5.37—
Dec 2022$-13M$0M$-13M$-8.77—
Dec 2021$-6M$0M$-7M$-0.02—
Dec 2020$-6M$0M$-6M$-0.03—
Dec 2019$-6M——$-0.05—
Dec 2018$-4M$0M$-4M$-0.16—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-10M—Dec ’24Three months to Mar 2025: revenue —, net income $-11M—Mar ’25Three months to Jun 2025: revenue —, net income $-18M—Jun ’25Three months to Sep 2025: revenue —, net income $-13M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-14M—Dec ’25Three months to Mar 2026: revenue —, net income $-13M—Mar ’26Three months to Jun 2026: revenue —, net income $-11M—Jun ’26Three months to Sep 2026: revenue —, net income $0M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Skye Bioscience Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-58 M
Net income
$-56 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$28 M
Total liabilities
$8 M
Total equity
$20 M

As of December-2025

Top 29 institutional investors in Skye Bioscience Inc.#

As of Sep 30, 2026
29 institutions held 1.9 M shares (about 5.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 5.3%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Skye Bioscience Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
15AM Venture Management, LLC981,269New2.77%$2 MNov 16, 2026
2Versant Venture Management, LLC250,962New0.71%$0 MNov 13, 2026
3Tang Capital Management LLC200,000New0.56%$0 MNov 16, 2026
4Baker Bros. Advisors LP196,905New0.56%$0 MNov 16, 2026
5Citadel Advisors LLC114,938New0.32%$0 MNov 16, 2026
6UBS Group AG40,461New0.11%$0 MNov 10, 2026
7BlackRock, Inc.29,107New0.08%$0 MNov 13, 2026
8Geode Capital Management, LLC27,254New0.08%$0 MNov 6, 2026
9Vanguard Capital Management LLC25,985New0.07%$0 MNov 13, 2026
10Jane Street Group, LLC18,688New0.05%$0 MNov 12, 2026
11Millennium Management LLC14,611New0.04%$0 MNov 16, 2026
12Vanguard Fiduciary Trust Co11,493New0.03%$0 MNov 13, 2026
13Virtu Financial LLC11,173New0.03%$0 MNov 17, 2026
14Royal Bank Of Canada1,129New0.00%$0 MNov 16, 2026
15Tower Research Capital LLC (TRC)1,093New0.00%$0 MNov 16, 2026
16Vanguard Global Advisers, LLC569New0.00%$0 MNov 13, 2026
17Nuveen, LLC295New0.00%$0 MNov 10, 2026
18Morgan Stanley243New0.00%$0 MNov 13, 2026
19Group One Trading LLC72New0.00%$0 MNov 10, 2026
20National Bank Of Canada /fi/50New0.00%$0 MNov 16, 2026
21TD Waterhouse Canada Inc.43New0.00%$0 MOct 16, 2026
22Robinhood Markets, Inc.24—0.00%$0 MNov 18, 2026
23Luminist Capital LLC12New0.00%$0 MNov 10, 2026
24Jpmorgan Chase & Co7New0.00%$0 MNov 12, 2026
25Federation des caisses Desjardins du Quebec5New0.00%$0 MNov 16, 2026
Show all 29: investors 26 to 29
Institutional investors 26 to 29 in Skye Bioscience Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Rockefeller Capital Management L.P.4New0.00%$0 MNov 13, 2026
27SouthState Bank Corp3New0.00%$0 MNov 9, 2026
28Danske Bank A/s1New0.00%$0 MNov 9, 2026
29CoreCap Advisors, LLC1New0.00%$0 MOct 8, 2026

Mutual funds holding Skye Bioscience Inc.#

7 funds hold shares worth $1 M (about 2.7% of the company). Since their previous reports 1 added shares and 4 sold, selling $0 M net.
Mutual funds holding Skye Bioscience Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.561,832$0 M1.6%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.184,978$0 M0.52%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC132,808$0 M0.37%<0.01%+32%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC30,637$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC24,379$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC18,888$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.17,072$0 M0.05%<0.01%−3.3%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Skye Bioscience Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$445 K
30 sales, 4 insiders
Net, 12 months
-$445 K
open market only
Insiders on file
26
since
$12.0 M-$1.8 M$0Jan 2024: bought $12.0 M (1 trades), sold $0 (0 trades)Jan 24Mar 2024: bought $4.5 M (1 trades), sold $0 (0 trades)MarSep 2024: bought $0 (0 trades), sold $1.8 M (12 trades)SepNov 2024: bought $0 (0 trades), sold $1.2 M (8 trades)NovAug 2025: bought $0 (0 trades), sold $801 K (8 trades)AugAug 2026: bought $0 (0 trades), sold $140 K (18 trades)AugSep 2026: bought $0 (0 trades), sold $304 K (12 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Skye Bioscience Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Andrew J. SchwabDirector, 10% ownerSellindirect-114,851$1.610—0Form 4
filed 5AM Ventures II LP10% ownerSellindirect-114,851$1.610$185 K0Form 4
filed Andrew J. SchwabDirector, 10% ownerSellindirect-4,528$1.610—0Form 4
filed 5AM Ventures II LP10% ownerSellindirect-4,528$1.610$7 K0Form 4
filed 5AM Ventures II LP10% ownerSellindirect-27,612$1.650$46 K114,851Form 4
filed Andrew J. SchwabDirector, 10% ownerSellindirect-27,612$1.650—114,851Form 4
filed Andrew J. SchwabDirector, 10% ownerSellindirect-1,088$1.650—4,528Form 4
filed 5AM Ventures II LP10% ownerSellindirect-1,088$1.650$2 K4,528Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Skye Bioscience Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
129,314
6.28 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-8 reverse split ; 1-for-250 reverse split

Trading halts

  • 2026-11-10 14:39 UTC, code LUDP, resumed 14:44 UTC
  • 2026-08-21 23:50 UTC, code T3, resumed 13:00 UTC
  • 2026-08-14 14:00 UTC, code LUDP, resumed 14:05 UTC
  • 2026-08-14 12:39 UTC, code T3, resumed 14:00 UTC
  • 2025-04-15 13:47 UTC, code LUDP, resumed 13:57 UTC

Fails to deliver

  • : 41 shares at $1.52
  • : 7 shares at $1.55
  • : 4,747 shares at $1.65
  • : 1,467 shares at $1.62
  • : 1 shares at $1.60

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Skye Bioscience Inc. scorecard#

Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.3×Price to book 0.3× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.41 vs -0.73Diluted EPS -1.41 in fiscal 2025 against -0.73 the year before (report's currency).
    • ✗Net income higher than five years earlier-$56 M-$56 M in fiscal 2025 against -$7 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$56 MNet income -$56 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-126.8%-126.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.3×Current ratio 3.30 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year8.7%Diluted shares up 8.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Skye Bioscience Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Skye Bioscience Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development42195.86.02.91.92.20.30.30.9
General and administrative16187.96.14.94.34.44.43.53.5
Operating expenses583035187.86.36.64.73.94.5
Operating income−58−30−35−18−7.8−6.3−6.6−4.7−3.9−4.5
Interest and finance income1.93.00.10.00.00.00.00.0——
Interest expense and finance costs00.70.90.70.80.71.00.10.0—
Other non-operating income (expense)2.23.6−2.9−1.2−0.7−0.37.7−15——
Income before tax−56−27−38−19−8.5−6.61.1−19−3.1−3.2
Income tax0.00.00.00.00.00.00.00.00.00.0
Net income attributable to shareholders−56−27−38−19−8.5−6.61.1−19−3.1−3.2
Earnings per share, basic-1.41-0.73-5.37-8.77r-0.02-0.030.01-0.16-0.11-0.17
Earnings per share, diluted-1.41-0.73-5.37-8.77r-0.02-0.03-0.05-0.16-0.11-0.17
Shares, weighted average (basic)40367.02.2r4072311351212819
Shares, weighted average (diluted)40367.02.2r4072311701212819
Balance sheet
Cash and cash equivalents5.9681.31.29.02.51.81.90.30.1
Short-term investments200————————
Other current assets0.92.21.1r0.5r0.10.0r0.00.0—0.0
Current assets2771128.99.62.72.02.00.60.3
Property, plant and equipment0.91.40.00.10.10.00.00.00.00.0
Right-of-use (leased) assets0.30.40.20.10.10————
Total assets2873129.19.92.72.02.00.60.3
Accounts payable2.00.61.21.70.90.40.10.00.10.3
Current liabilities8.24.314123.90.81.0160.80.7
Lease liabilities (non-current)0.10.30.200.10————
Non-current liabilities————————0.61.1
Total liabilities8.34.614124.02.21.4181.41.8
Retained earnings−187−131−104−67−47−39−32−33−14−11
Shareholders' equity2068−2.1−3.05.90.50.5−16−3.6−2.9
Total liabilities and equity2873129.19.92.72.02.00.60.3
Shares outstanding4.2r31123.7r476288183134r3422
Cash-flow statement
Depreciation and amortization0.70.30.1———————
Share-based compensation7.88.31.00.60.90.30.70.70.60.7
Cash from operating activities−43−25−14−13−6.5−6.1−6.0−3.9−3.3r−3.6
Capital expenditure−0.0−1.6−0.0−0.0−0.1−0.0—−0.0−0.0−0.0
Cash from investing activities−20−0.26.65.2−0.1−0.0—−0.0−0.0−0.0
Shares issued—05.006.16.11.93.1—0.4
Cash from financing activities0.08416−0.2136.76.05.53.50.4
Change in cash−63589.1−7.76.50.6−0.01.60.2r−3.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Skye Bioscience Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Skye Bioscience Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Skye Bioscience Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.4 M
Mr. Dhillon
Other top executives, average
$882 K
the CEO earned 1.5× this
$100 invested is now
$19
Skye Bioscience Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Dhillon$1.4 M−$148 K$882 K$19
2024Punit Dhillon$6.1 M$2.8 M$2.2 M$70
2023Punit Dhillon$1.8 M$1.3 M$1.3 M$67

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Skye Bioscience Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 3 · Auditor changed 1 · Change in control 1 · Directors and officers 10 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 6

Skye Bioscience Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officersAgreement ended8-K
Material agreementUnregistered share sale8-K
Shareholder rights changed8-K/A
Delisting notice8-K
Change in controlDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Bylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Directors and officers8-K/A
Directors and officers8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Auditor changedShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 11, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Skye Bioscience Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$40 MPrivate placement after listing$10 to $50 million13equitySEC
Jan 2024$50 MPrivate placement after listing$10 to $50 million11equity, optionsSEC
Aug 2023$62 MPrivate placement after listing$50 to $250 million12equity, debt, optionsSEC
Nov 2018$2 MPrivate placement after listing$2 to $10 million1equity, debt, optionsSEC
Jan 2018$4 MPrivate placement after listing$2 to $10 million2equity, debt, optionsSEC
Nov 2017$2 MPrivate placement after listing$2 to $10 million2equitySEC
Jan 2017$1 MPrivate placement after listingUnder $2 million5equitySEC
Aug 2015$5 MPrivate placement after listing$2 to $10 million15equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Skye Bioscience Inc. compares in Biotechnology

  • Market cap$7 M · higher than 8% of 726
  • Price / book0.3× · lower than 96% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Skye Bioscience Inc.🇺🇸$7 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 9, 2026
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Skye Bioscience Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Skye Bioscience Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Skye Bioscience Inc.? Suggest a correction